O tratamento com óleo de coco virgem (Cocos nucifera L.) melhora os parâmetros murinométricos, a função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticos
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Biblioteca Digital de Teses e Dissertações da UFPB |
Texto Completo: | https://repositorio.ufpb.br/jspui/handle/123456789/24028 |
Resumo: | The incidence of obese asthmatic patients has increased in recent years, but little is known about the characteristics and therapeutic alternatives for the management of these associated comorbidities. A possible alternative for the treatment of obesity-exacerbated asthma is virgin coconut oil (VCO), which has already demonstrated a beneficial effect in a model of chronic allergic lung inflammation in guinea pigs. Therefore, the objective was to evaluate a possible effect of OCV on murinometric parameters, pulmonary function and tracheal reactivity in obese Wistar rats with asthma. Initially, a behavioral screening and evaluation of the toxicity of repeated doses of VCO in male and female rats (n = 5) was performed. To perform the other parameters, the animals were divided into four experimental groups (n = 6): control (CG), obese asthmatic (OAG) and obese asthmatic treated with VCO at doses of 1000 (OAVCOG1000) and 2000 mg/kg (OAVCOG2000). To induce this disorder, the animals received a high glycemic index and load (HGLID) diet for 16 weeks and were sensitized and nebulized with ovalbumin (OVA) during the last 21 days of the 16 weeks and the GOAOCV animals received the OCV in the last in the last 30 days. All experimental protocols were approved by CEUA/UFPB (9133040520). It was observed that VCO at doses of 1000 and 2000 mg/kg/day did not promote any behavioral change, did not induce deaths in animal, and there were no changes in feed consumption and weight of the animals. However, VCO (1000/2000 mg/kg/day) decreased fasting blood glucose in rats (95.2 ± 1.7 and 108.4 ± 2.1 mg/dL, respectively), when compared to CG (124 .3 ± 1.3 mg/dL). In female rats, only the dose of 2000 mg/kg/day (103.2 ± 3.4 mg/dL) reduced fasting blood glucose when compared to the CG (119.0 ± 1.1 mg/dL). Regarding the weight of the different organs, only the female rats treated with VCO 2000 mg/kg/day showed an increase in spleen weight (0.27 ± 0.01 g) and a decrease in liver weight (3.0 ± 0.1 g), when compared to the CG (0.2 ± 0.01 and 3.5 ± 0.14 g, respectively). In the evaluation of experimental obesity, it was observed that the ingestion of HGLID increased the body weight of the animals in the AOG (460.2 ± 21.0 g), when compared to the CG (365.2 ± 3.5 g), and the treatment with VCO at a dose of 2000 mg/kg/day (410.2 ± 9.8 g), prevented this increase. No changes were observed in daily feed intake between the experimental groups. Regarding murinometric parameters, treatment with VCO at doses of 1000 (95.3 ± 3.3 mg/dL) and 2000 mg/kg/day (104.2 ± 6.2 mg/dL) decreased fasting blood glucose. of these animals, compared to AOG (113.8 ± 6.1 mg/dL). Differently, in both doses, the VCO did not change the nasal length, Lee index, BMI and chest circumference. However, the dose of 2000 mg/kg/day (19.1 ± 0.2 cm) prevented the increase in abdominal circumference when compared to the CG (18.8 ± 0.3 cm). Regarding fat deposits, it was observed that treatment with VCO at doses of 1000 and 2000 mg/kg/day reversed the increase in this tissue caused by the ingestion of HGLID, in addition to reducing the adiposity index by about 43.5 e 64.1%. During the asthma induction period, the pulmonary function (tidal volume, respiratory rate and minute volume) of these animals was evaluated. It was observed that treatment with VCO at a dose of 2000 mg/kg/day reversed the reduction in respiratory rate and tidal volume caused by the disorder. Regarding the contractile reactivity of the trachea of asthmatic and obese rats, treatment with VCO (1000 and 2000 mg/kg/day) did not alter the contractions induced by KCl. When this contraction was induced by carbachol, only at the dose of 2000 mg/kg/day of VCO there was a reversal of the tracheal hyperresponsiveness caused by this disorder. It was further observed that treatment with VCO led to a reduction in the relaxing potency of nifedipine, but did not alter the relaxation induced by aminophylline. In view of this, it can be concluded that VCO can become a promising therapeutic alternative in the treatment of associated asthma and obesity. |
id |
UFPB_5494a6c0351b280643add214076cc1b5 |
---|---|
oai_identifier_str |
oai:repositorio.ufpb.br:123456789/24028 |
network_acronym_str |
UFPB |
network_name_str |
Biblioteca Digital de Teses e Dissertações da UFPB |
repository_id_str |
|
spelling |
O tratamento com óleo de coco virgem (Cocos nucifera L.) melhora os parâmetros murinométricos, a função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticosÓleo de coco virgemAsmaObesidadeAsma exacerbada pela obesidadeVirgin coconut oilAsthmaObesityObesity-exacerbated asthmaCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIAThe incidence of obese asthmatic patients has increased in recent years, but little is known about the characteristics and therapeutic alternatives for the management of these associated comorbidities. A possible alternative for the treatment of obesity-exacerbated asthma is virgin coconut oil (VCO), which has already demonstrated a beneficial effect in a model of chronic allergic lung inflammation in guinea pigs. Therefore, the objective was to evaluate a possible effect of OCV on murinometric parameters, pulmonary function and tracheal reactivity in obese Wistar rats with asthma. Initially, a behavioral screening and evaluation of the toxicity of repeated doses of VCO in male and female rats (n = 5) was performed. To perform the other parameters, the animals were divided into four experimental groups (n = 6): control (CG), obese asthmatic (OAG) and obese asthmatic treated with VCO at doses of 1000 (OAVCOG1000) and 2000 mg/kg (OAVCOG2000). To induce this disorder, the animals received a high glycemic index and load (HGLID) diet for 16 weeks and were sensitized and nebulized with ovalbumin (OVA) during the last 21 days of the 16 weeks and the GOAOCV animals received the OCV in the last in the last 30 days. All experimental protocols were approved by CEUA/UFPB (9133040520). It was observed that VCO at doses of 1000 and 2000 mg/kg/day did not promote any behavioral change, did not induce deaths in animal, and there were no changes in feed consumption and weight of the animals. However, VCO (1000/2000 mg/kg/day) decreased fasting blood glucose in rats (95.2 ± 1.7 and 108.4 ± 2.1 mg/dL, respectively), when compared to CG (124 .3 ± 1.3 mg/dL). In female rats, only the dose of 2000 mg/kg/day (103.2 ± 3.4 mg/dL) reduced fasting blood glucose when compared to the CG (119.0 ± 1.1 mg/dL). Regarding the weight of the different organs, only the female rats treated with VCO 2000 mg/kg/day showed an increase in spleen weight (0.27 ± 0.01 g) and a decrease in liver weight (3.0 ± 0.1 g), when compared to the CG (0.2 ± 0.01 and 3.5 ± 0.14 g, respectively). In the evaluation of experimental obesity, it was observed that the ingestion of HGLID increased the body weight of the animals in the AOG (460.2 ± 21.0 g), when compared to the CG (365.2 ± 3.5 g), and the treatment with VCO at a dose of 2000 mg/kg/day (410.2 ± 9.8 g), prevented this increase. No changes were observed in daily feed intake between the experimental groups. Regarding murinometric parameters, treatment with VCO at doses of 1000 (95.3 ± 3.3 mg/dL) and 2000 mg/kg/day (104.2 ± 6.2 mg/dL) decreased fasting blood glucose. of these animals, compared to AOG (113.8 ± 6.1 mg/dL). Differently, in both doses, the VCO did not change the nasal length, Lee index, BMI and chest circumference. However, the dose of 2000 mg/kg/day (19.1 ± 0.2 cm) prevented the increase in abdominal circumference when compared to the CG (18.8 ± 0.3 cm). Regarding fat deposits, it was observed that treatment with VCO at doses of 1000 and 2000 mg/kg/day reversed the increase in this tissue caused by the ingestion of HGLID, in addition to reducing the adiposity index by about 43.5 e 64.1%. During the asthma induction period, the pulmonary function (tidal volume, respiratory rate and minute volume) of these animals was evaluated. It was observed that treatment with VCO at a dose of 2000 mg/kg/day reversed the reduction in respiratory rate and tidal volume caused by the disorder. Regarding the contractile reactivity of the trachea of asthmatic and obese rats, treatment with VCO (1000 and 2000 mg/kg/day) did not alter the contractions induced by KCl. When this contraction was induced by carbachol, only at the dose of 2000 mg/kg/day of VCO there was a reversal of the tracheal hyperresponsiveness caused by this disorder. It was further observed that treatment with VCO led to a reduction in the relaxing potency of nifedipine, but did not alter the relaxation induced by aminophylline. In view of this, it can be concluded that VCO can become a promising therapeutic alternative in the treatment of associated asthma and obesity.Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPqA incidência de pacientes asmáticos com obesidade tem aumentado nos últimos anos, porém pouco se sabe sobre as características e alternativas terapêuticas para o manejo dessas comorbidades associadas. Uma possível alternativa para o tratamento da asma exacerbada pela obesidade é o óleo de coco virgem (OCV), que já demonstrou efeito benéfico em um modelo de inflamação pulmonar alérgica crônica em cobaias. Diante disso, objetivou-se avaliar um possível efeito do OCV sobre os parâmetros murinométricos, função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticos. Inicialmente foi realizada uma triagem comportamental e avaliação da toxicidade de doses repetidas do OCV em ratos e ratas (n = 5). Para realização dos demais parâmetros os animais foram divididos em quatro grupos experimentais (n = 6): controle (GC), obeso asmático (GOA) e obeso asmático tratados com o OCV nas doses de 1000 (GOAOCV1000) e 2000 mg/kg (GOAOCV2000). Para indução dessa desordem, os animais receberam durante 16 semanas uma dieta de alto índice glicêmico (DAIG) e foram sensibilizados e nebulizados com ovalbumina (OVA) durante os últimos 21 dias das 16 semanas e os animais do GOAOCV recebeu o OCV nos últimos nos últimos 30 dias. Todos os protocolos experimentais foram aprovados pela CEUA/UFPB (9133040520). Foi observado que o OCV nas doses de 1000 e 2000 mg/kg/dia não promoveu nenhuma alteração comportamental, não induziu mortes, e não houve alterações no consumo de ração e peso dos animais. Entretanto, o OVC (1000/2000 mg/kg/dia) diminuiu a glicemia de jejum dos ratos (95,2 ± 1,7 e 108,4 ± 2,1 mg/dL, respectivamente), quando comparado ao GC (124,3 ± 1,3 mg/dL). Já nas ratas, apenas a dose de 2000 mg/kg/dia (103,2 ± 3,4 mg/dL) reduziu a glicemia de jejum, quando comparado ao GC (119,0 ± 1,1 mg/dL). Com relação ao peso dos diferentes órgãos, apenas as ratas tratadas com OCV 2000 mg/kg/dia apresentaram um aumento no peso do baço (0,27 ± 0,01 g) e diminuição do peso do fígado (3,0 ± 0,1 g), quando comparado ao GC (0,2 ± 0,01 e 3,5 ± 0,14 g, respectivamente). Na avaliação da obesidade experimental, foi observado que a ingestão da DAIG aumentou o peso corporal dos animais do GOA (460,2 ± 21,0 g), quando comparado ao GC (365,2 ± 3,5 g), e o tratamento com OCV na dose de 2000 mg/kg/dia (410,2 ± 9,8 g), preveniu esse aumento. Não foram observadas alterações no consumo diário de ração entre os grupos experimentais. Em relação aos parâmetros murinométricos, o tratamento com OCV nas doses de 1000 (95,3 ± 3,3 mg/dL) e 2000 mg/kg/dia (104,2 ± 6,2 mg/dL) diminuiu a glicemia de jejum destes animais, comparado ao GOA (113,8 ± 6,1 mg/dL). Diferentemente, em ambas as doses, o OCV não alterou o comprimento nasonal, índice de Lee, IMC e circunferência torácica. Porém, a dose de 2000 mg/kg/dia (19,1 ± 0,2 cm) preveniu o aumento da circunferência abdominal, quando comparado ao GC (18,8 ± 0,3 cm). Com relação aos depósitos de gorduras foi observado que o tratamento com o OCV nas doses de 1000 e 2000 mg/kg/dia reverteu o aumento desse tecido, ocasionado pela ingestão da DAIG, além de reduzir o índice de adiposidade em cerca de cerca de 43,5 e 64,1%. Durante o período de indução da asma foi avaliada a função pulmonar (volume corrente, frequência respiratória e volume minuto) destes animais. Observou-se que o tratamento com OCV na dose de 2000 mg/kg/dia, reverteu a redução da frequência respiratória e do volume corrente ocasionada pela desordem. Com relação à reatividade contrátil da traqueia de ratos asmáticos e obesos, o tratamento com OCV (1000 e 2000 mg/kg/dia) não alterou as contrações induzidas por KCl. Já quando essa contração era induzida pelo carbacol, apenas na dose de 2000 mg/kg/dia do OCV houve reversão da hiper-responsividade traqueal ocasionada por esta desordem. Observou-se ainda que o tratamento com o OCV levou a uma redução na potência relaxante do nifedipino, mas não alterou o relaxamento induzido pela aminofilina. Diante disso, pode-se concluir que o OCV pode se tornar uma alternativa terapêutica promissora no tratamento da asma e obesidade associadas.Universidade Federal da ParaíbaBrasilFarmacologiaPrograma de Pós-Graduação em Produtos Naturais e Sintéticos BioativosUFPBCavalcante, Fabiana de Andradehttp://lattes.cnpq.br/2233846820438278Pessoa, Rayane Fernandes2022-07-27T19:54:21Z2022-05-242022-07-27T19:54:21Z2022-02-23info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttps://repositorio.ufpb.br/jspui/handle/123456789/24028porAttribution-NoDerivs 3.0 Brazilhttp://creativecommons.org/licenses/by-nd/3.0/br/info:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFPBinstname:Universidade Federal da Paraíba (UFPB)instacron:UFPB2022-08-09T12:10:26Zoai:repositorio.ufpb.br:123456789/24028Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufpb.br/PUBhttp://tede.biblioteca.ufpb.br:8080/oai/requestdiretoria@ufpb.br|| diretoria@ufpb.bropendoar:2022-08-09T12:10:26Biblioteca Digital de Teses e Dissertações da UFPB - Universidade Federal da Paraíba (UFPB)false |
dc.title.none.fl_str_mv |
O tratamento com óleo de coco virgem (Cocos nucifera L.) melhora os parâmetros murinométricos, a função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticos |
title |
O tratamento com óleo de coco virgem (Cocos nucifera L.) melhora os parâmetros murinométricos, a função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticos |
spellingShingle |
O tratamento com óleo de coco virgem (Cocos nucifera L.) melhora os parâmetros murinométricos, a função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticos Pessoa, Rayane Fernandes Óleo de coco virgem Asma Obesidade Asma exacerbada pela obesidade Virgin coconut oil Asthma Obesity Obesity-exacerbated asthma CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
title_short |
O tratamento com óleo de coco virgem (Cocos nucifera L.) melhora os parâmetros murinométricos, a função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticos |
title_full |
O tratamento com óleo de coco virgem (Cocos nucifera L.) melhora os parâmetros murinométricos, a função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticos |
title_fullStr |
O tratamento com óleo de coco virgem (Cocos nucifera L.) melhora os parâmetros murinométricos, a função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticos |
title_full_unstemmed |
O tratamento com óleo de coco virgem (Cocos nucifera L.) melhora os parâmetros murinométricos, a função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticos |
title_sort |
O tratamento com óleo de coco virgem (Cocos nucifera L.) melhora os parâmetros murinométricos, a função pulmonar e a reatividade traqueal de ratos Wistar obesos asmáticos |
author |
Pessoa, Rayane Fernandes |
author_facet |
Pessoa, Rayane Fernandes |
author_role |
author |
dc.contributor.none.fl_str_mv |
Cavalcante, Fabiana de Andrade http://lattes.cnpq.br/2233846820438278 |
dc.contributor.author.fl_str_mv |
Pessoa, Rayane Fernandes |
dc.subject.por.fl_str_mv |
Óleo de coco virgem Asma Obesidade Asma exacerbada pela obesidade Virgin coconut oil Asthma Obesity Obesity-exacerbated asthma CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
topic |
Óleo de coco virgem Asma Obesidade Asma exacerbada pela obesidade Virgin coconut oil Asthma Obesity Obesity-exacerbated asthma CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA |
description |
The incidence of obese asthmatic patients has increased in recent years, but little is known about the characteristics and therapeutic alternatives for the management of these associated comorbidities. A possible alternative for the treatment of obesity-exacerbated asthma is virgin coconut oil (VCO), which has already demonstrated a beneficial effect in a model of chronic allergic lung inflammation in guinea pigs. Therefore, the objective was to evaluate a possible effect of OCV on murinometric parameters, pulmonary function and tracheal reactivity in obese Wistar rats with asthma. Initially, a behavioral screening and evaluation of the toxicity of repeated doses of VCO in male and female rats (n = 5) was performed. To perform the other parameters, the animals were divided into four experimental groups (n = 6): control (CG), obese asthmatic (OAG) and obese asthmatic treated with VCO at doses of 1000 (OAVCOG1000) and 2000 mg/kg (OAVCOG2000). To induce this disorder, the animals received a high glycemic index and load (HGLID) diet for 16 weeks and were sensitized and nebulized with ovalbumin (OVA) during the last 21 days of the 16 weeks and the GOAOCV animals received the OCV in the last in the last 30 days. All experimental protocols were approved by CEUA/UFPB (9133040520). It was observed that VCO at doses of 1000 and 2000 mg/kg/day did not promote any behavioral change, did not induce deaths in animal, and there were no changes in feed consumption and weight of the animals. However, VCO (1000/2000 mg/kg/day) decreased fasting blood glucose in rats (95.2 ± 1.7 and 108.4 ± 2.1 mg/dL, respectively), when compared to CG (124 .3 ± 1.3 mg/dL). In female rats, only the dose of 2000 mg/kg/day (103.2 ± 3.4 mg/dL) reduced fasting blood glucose when compared to the CG (119.0 ± 1.1 mg/dL). Regarding the weight of the different organs, only the female rats treated with VCO 2000 mg/kg/day showed an increase in spleen weight (0.27 ± 0.01 g) and a decrease in liver weight (3.0 ± 0.1 g), when compared to the CG (0.2 ± 0.01 and 3.5 ± 0.14 g, respectively). In the evaluation of experimental obesity, it was observed that the ingestion of HGLID increased the body weight of the animals in the AOG (460.2 ± 21.0 g), when compared to the CG (365.2 ± 3.5 g), and the treatment with VCO at a dose of 2000 mg/kg/day (410.2 ± 9.8 g), prevented this increase. No changes were observed in daily feed intake between the experimental groups. Regarding murinometric parameters, treatment with VCO at doses of 1000 (95.3 ± 3.3 mg/dL) and 2000 mg/kg/day (104.2 ± 6.2 mg/dL) decreased fasting blood glucose. of these animals, compared to AOG (113.8 ± 6.1 mg/dL). Differently, in both doses, the VCO did not change the nasal length, Lee index, BMI and chest circumference. However, the dose of 2000 mg/kg/day (19.1 ± 0.2 cm) prevented the increase in abdominal circumference when compared to the CG (18.8 ± 0.3 cm). Regarding fat deposits, it was observed that treatment with VCO at doses of 1000 and 2000 mg/kg/day reversed the increase in this tissue caused by the ingestion of HGLID, in addition to reducing the adiposity index by about 43.5 e 64.1%. During the asthma induction period, the pulmonary function (tidal volume, respiratory rate and minute volume) of these animals was evaluated. It was observed that treatment with VCO at a dose of 2000 mg/kg/day reversed the reduction in respiratory rate and tidal volume caused by the disorder. Regarding the contractile reactivity of the trachea of asthmatic and obese rats, treatment with VCO (1000 and 2000 mg/kg/day) did not alter the contractions induced by KCl. When this contraction was induced by carbachol, only at the dose of 2000 mg/kg/day of VCO there was a reversal of the tracheal hyperresponsiveness caused by this disorder. It was further observed that treatment with VCO led to a reduction in the relaxing potency of nifedipine, but did not alter the relaxation induced by aminophylline. In view of this, it can be concluded that VCO can become a promising therapeutic alternative in the treatment of associated asthma and obesity. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-07-27T19:54:21Z 2022-05-24 2022-07-27T19:54:21Z 2022-02-23 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufpb.br/jspui/handle/123456789/24028 |
url |
https://repositorio.ufpb.br/jspui/handle/123456789/24028 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
Attribution-NoDerivs 3.0 Brazil http://creativecommons.org/licenses/by-nd/3.0/br/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution-NoDerivs 3.0 Brazil http://creativecommons.org/licenses/by-nd/3.0/br/ |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Universidade Federal da Paraíba Brasil Farmacologia Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos UFPB |
publisher.none.fl_str_mv |
Universidade Federal da Paraíba Brasil Farmacologia Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos UFPB |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da UFPB instname:Universidade Federal da Paraíba (UFPB) instacron:UFPB |
instname_str |
Universidade Federal da Paraíba (UFPB) |
instacron_str |
UFPB |
institution |
UFPB |
reponame_str |
Biblioteca Digital de Teses e Dissertações da UFPB |
collection |
Biblioteca Digital de Teses e Dissertações da UFPB |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações da UFPB - Universidade Federal da Paraíba (UFPB) |
repository.mail.fl_str_mv |
diretoria@ufpb.br|| diretoria@ufpb.br |
_version_ |
1801842997362425856 |